Amolyt Pharma Appoints Mark Sumeray, MD, as Chief Medical Officer | citybiz
Mark Sumeray MD MS FRCS - Chief Medical Officer @ Amolyt Pharma - Emails and Phone Numbers | FlashIntel
Michael Paniccia - "Starstruck" 7in Single
Empowered Patient Podcast: Using Therapeutic Peptides to Treat Permanent Hypoparathyroidism with Mark Sumeray MD Amolyt Pharma TRANSCRIPT
Talking AZP-3601 for Hypoparathyroidism (Pt. 1) - Patient Worthy
Mark Sumeray - Chief Medical Officer @ Amolyt Pharma - Crunchbase Person Profile
Mark Sumeray MD MS FRCS - Chief Medical Officer at Amolyt Pharma | The Org
Multi-Mark Werkzeug von Kreg - YouTube
Mark Sumeray MD MS FRCS - Amolyt Pharma | LinkedIn
Amolyt Pharma (@AmolytPharma) / X
PDF) Oleogel-S10 Phase 3 study “EASE” for epidermolysis bullosa: study design and rationale
Hypoparathyroidism information webinar - Parathyroid UK
Mark Sumeray MD MS FRCS - Amolyt Pharma | LinkedIn
Mark Sumeray - Chief Medical Officer @ Amolyt Pharma - Crunchbase Person Profile
Mark Sumeray MD MS FRCS - Amolyt Pharma | LinkedIn
Podcast:Everybody Has a Thyroid... What Could Go Wrong??? Dr. Mark Sumeray, CMO of Amolyt Pharma:Moira Gunn
ProQuest Dissertations
Sarah Sumeray | Secret Artists with Annie McGrath on Acast
Mark Sumeray MD MS FRCS - Amolyt Pharma | LinkedIn
